ACH-126: Achillion began a double-blind, North American Phase II trial in 60 HIV infected patients who will receive combination therapy with lamivudine or with

Achillion Pharmaceuticals Inc., New Haven, Conn. Product: ACH-126,443 ( beta-L-Fd4C) Business: Infectious diseases Therapeutic category: Viral replication Target: NA Description: Oral nucleoside anal...